C Lees1, S Weerasinghe2, N Lamond3, T Younis3, R Ramjeesingh3. 1. Division of Palliative Medicine, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS. 2. Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS. 3. Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS.
Abstract
Background: Palliative care (pc) consultation has been associated with less aggressive care at end of life in a number of malignancies, but the effect of the consultation timing has not yet been fully characterized. For patients with unresectable pancreatic cancer (upcc), aggressive and resource-intensive treatment at the end of life can be costly, but not necessarily of better quality. In the present study, we investigated the association, if any, between the timing of specialist pc consultation and indicators of aggressive care at end of life in patients with upcc. Methods: This retrospective cohort study examined the potential effect of the timing of specialist pc consultation on key indicators of aggressive care at end of life in all patients diagnosed with upcc in Nova Scotia between 1 January 2010 and 31 December 2015. Statistical analysis included univariable and multivariable logistic regression. Results: In the 365 patients identified for inclusion in the study, specialist pc consultation was found to be associated with decreased odds of experiencing an indicator of aggressive care at end of life; however, the timing of the consultation was not significant. Residency in an urban area was associated with decreased odds of experiencing an indicator of aggressive care at end of life. We observed no association between experiencing an indicator of aggressive care at end of life and consultation with medical oncology or radiation oncology. Conclusions: Regardless of timing, specialist pc consultation was associated with decreased odds of experiencing an indicator of aggressive care at end of life. That finding provides further evidence to support the integral role of pc in managing patients with a life-limiting malignancy.
Background: Palliative care (pc) consultation has been associated with less aggressive care at end of life in a number of malignancies, but the effect of the consultation timing has not yet been fully characterized. For patients with unresectable pancreatic cancer (upcc), aggressive and resource-intensive treatment at the end of life can be costly, but not necessarily of better quality. In the present study, we investigated the association, if any, between the timing of specialist pc consultation and indicators of aggressive care at end of life in patients with upcc. Methods: This retrospective cohort study examined the potential effect of the timing of specialist pc consultation on key indicators of aggressive care at end of life in all patients diagnosed with upcc in Nova Scotia between 1 January 2010 and 31 December 2015. Statistical analysis included univariable and multivariable logistic regression. Results: In the 365 patients identified for inclusion in the study, specialist pc consultation was found to be associated with decreased odds of experiencing an indicator of aggressive care at end of life; however, the timing of the consultation was not significant. Residency in an urban area was associated with decreased odds of experiencing an indicator of aggressive care at end of life. We observed no association between experiencing an indicator of aggressive care at end of life and consultation with medical oncology or radiation oncology. Conclusions: Regardless of timing, specialist pc consultation was associated with decreased odds of experiencing an indicator of aggressive care at end of life. That finding provides further evidence to support the integral role of pc in managing patients with a life-limiting malignancy.
Entities:
Keywords:
Pancreatic cancer; aggressive care; palliative care
Authors: Craig C Earle; Elyse R Park; Bonnie Lai; Jane C Weeks; John Z Ayanian; Susan Block Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: B Laquente; A Calsina-Berna; A Carmona-Bayonas; P Jiménez-Fonseca; I Peiró; A Carrato Journal: Clin Transl Oncol Date: 2017-06-13 Impact factor: 3.405
Authors: Raymond W Jang; Monika K Krzyzanowska; Camilla Zimmermann; Nathan Taback; Shabbir M H Alibhai Journal: J Natl Cancer Inst Date: 2015-01-20 Impact factor: 13.506
Authors: Mary Ersek; Susan C Miller; Todd H Wagner; Joshua M Thorpe; Dawn Smith; Cari R Levy; Risha Gidwani; Katherine Faricy-Anderson; Karl A Lorenz; Bruce Kinosian; Vincent Mor Journal: Cancer Date: 2017-04-17 Impact factor: 6.860
Authors: Matthew C Cheung; Craig C Earle; Jagadish Rangrej; Thi H Ho; Ning Liu; Lisa Barbera; Refik Saskin; Joan Porter; Soo Jin Seung; Nicole Mittmann Journal: Cancer Date: 2015-05-29 Impact factor: 6.860
Authors: Mellar P Davis; Erin A Vanenkevort; Alexander Elder; Amanda Young; Irina D Correa Ordonez; Mark J Wojtowicz; Halle Ellison; Carlos Fernandez; Zankhana Mehta; Bertrand Behm; Glen Digwood; Rajiv Panikkar Journal: Support Care Cancer Date: 2022-03-15 Impact factor: 3.603
Authors: Leon Bruder; Larissa Schawe; Bernhard Gebauer; Jan Paul Frese; Maximilian de Bucourt; Katharina Beyer; Johann Pratschke; Andreas Greiner; Safwan Omran Journal: Curr Oncol Date: 2022-03-30 Impact factor: 3.109